# A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

> **NCT06026254** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **ImmuneSensor Therapeutics Inc.** · enrollment: 2 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** IMSA101
- **DRUG:** Immune Checkpoint Inhibitor

## Key facts

- **NCT ID:** NCT06026254
- **Lead sponsor:** ImmuneSensor Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-15
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06026254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06026254, "A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06026254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*